Technical Analysis for CDTX - Cidara Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Downtrend | Bearish | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -6.58% | |
| Gapped Down | Weakness | -6.58% | |
| 20 DMA Support | Bullish | -11.80% | |
| Narrow Range Bar | Range Contraction | -11.80% | |
| Inside Day | Range Contraction | -11.80% | |
| Wide Bands | Range Expansion | -11.80% | |
| Crossed Above 20 DMA | Bullish | -14.36% | |
| Wide Bands | Range Expansion | -14.36% |
| Alert | Time |
|---|---|
| Down 5% | 2 days ago |
| Down 3% | 2 days ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| 1.5x Volume Pace | 2 days ago |
| Fell Below Previous Day's Low | 2 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 06/21/2024
Cidara Therapeutics, Inc. Description
Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic Candida infections. The company also develops CD101 topical, a topical formulation of CD101 for the treatment of recurrent vulvovaginal candidiasis, a prevalent mucosal infection. In addition, it develops a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara Therapeutics is developing its first Cloudbreak development candidate, C001, for the treatment of invasive aspergillosis; and evaluating additional opportunities to expand its Cloudbreak immunotherapy platform to other areas of infectious disease. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Disease Immunotherapy Infectious Diseases Anti Infectives Vagina Candidiasis Immunotherapy Technology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 29.6 |
| 52 Week Low | 10.004 |
| Average Volume | 74,757 |
| 200-Day Moving Average | 15.86 |
| 50-Day Moving Average | 14.76 |
| 20-Day Moving Average | 12.32 |
| 10-Day Moving Average | 12.66 |
| Average True Range | 1.37 |
| RSI (14) | 42.86 |
| ADX | 30.36 |
| +DI | 23.88 |
| -DI | 27.00 |
| Chandelier Exit (Long, 3 ATRs) | 10.90 |
| Chandelier Exit (Short, 3 ATRs) | 14.10 |
| Upper Bollinger Bands | 14.07 |
| Lower Bollinger Band | 10.56 |
| Percent B (%b) | 0.18 |
| BandWidth | 28.44 |
| MACD Line | -0.76 |
| MACD Signal Line | -0.78 |
| MACD Histogram | 0.0233 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.89 | ||||
| Resistance 3 (R3) | 12.97 | 12.48 | 12.61 | ||
| Resistance 2 (R2) | 12.48 | 12.06 | 12.45 | 12.52 | |
| Resistance 1 (R1) | 11.85 | 11.79 | 11.61 | 11.77 | 12.42 |
| Pivot Point | 11.36 | 11.36 | 11.24 | 11.33 | 11.36 |
| Support 1 (S1) | 10.73 | 10.94 | 10.49 | 10.65 | 10.00 |
| Support 2 (S2) | 10.24 | 10.67 | 10.21 | 9.90 | |
| Support 3 (S3) | 9.61 | 10.24 | 9.81 | ||
| Support 4 (S4) | 9.53 |
